GlassScriptPhysician profile
George K Avetian
NPI 1851348718
$18,267.44
in general payments reported to CMS, 2019-2025
25 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $3,128 · 2022: $247 · 2023: $418 · 2024: $220 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emergent Biosolutions INC. | $10,833.86 | 2019 | |
| Novo Nordisk INC | $2,433.20 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $588.39 | 2019-2025 | Airsupra |
| Pfizer INC. | $551.21 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $531.53 | 2019-2023 | Spravato |
| Merck Sharp & Dohme LLC | $525.34 | 2019-2020 | |
| Amarin Pharma, INC. | $448.19 | 2019-2020 | |
| Lilly USA, LLC | $427.24 | 2019-2020 | |
| Amgen INC. | $286.98 | 2019 | |
| Glaxosmithkline, LLC. | $211.59 | 2019-2020 | |
| Medtronic, INC. | $171.23 | 2025 | Symplicity G3 |
| Abbvie INC. | $170.59 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.34 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $124.93 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $122.09 | 2024 | Sunosi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $122.09 | 2025 | Opsumit, Uptravi |
| Daiichi Sankyo INC. | $121.04 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.45 | 2023 | |
| Mylan Specialty L.P. | $100.57 | 2023 | Yupelri |
| Alkermes, INC. | $95.55 | 2023 | Vivitrol |
| Allergan, INC. | $44.69 | 2020 | |
| Genentech USA, INC. | $39.64 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.23 | 2019 | |
| Sanofi Pasteur INC. | $16.71 | 2020 | |
| Zyla Life Sciences, INC. | $14.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Avetian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.